Key result
P2Y14 receptor emerges as a promising therapeutic target for inflammatory and metabolic diseases.
Why the study?
The P2Y14 receptor plays crucial regulatory roles in diverse pathophysiological contexts, making it an attractive therapeutic target requiring review of its mechanisms and therapeutic inhibitors.
This review provides a theoretical basis and innovative direction for the future development of P2Y14R-targeted therapeutic drugs for inflammatory and metabolic diseases.
The P2Y 14 receptor (P2Y 14 R) is a G protein‐coupled receptor (GPCR) that can be activated by the extracellular nucleotide uridine diphosphate glucose (UDPG). It performs crucial regulatory roles in diverse pathophysiological contexts, such as immune modulation, inflammatory responses, tumor progression, and metabolic disorders. Therefore, it represents a highly attractive therapeutic target. This review elucidates the signal transduction mechanism of P2Y 14 R and its pathological functions in conditions such as gouty arthritis (GA) and neuropathic pain (NP). Meanwhile, P2Y 14 R inhibitors based on multiple drug discovery strategies are also comprehensively summarized. Furthermore, this review analyzes the key challenges currently faced in inhibitors research and development. By integrating the latest reported crystal structure of P2Y 14 R, it looks forward to the prospects of precise drug design based on structure and clinical translation. This provides a theoretical basis and innovative direction for the future development of P2Y 14 R‐targeted therapeutic drugs.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2026) conducted a review in Inflammatory and metabolic diseases. P2Y14 receptor inhibitors was evaluated. The P2Y14 receptor is a promising therapeutic target for inflammatory and metabolic diseases, with ongoing research focused on developing structure-based inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: